Oral drug may allow early treatment of diabetic retinopathy

Editor’s note: This is a developing news story. Please check back soon for updates.
Some patients with nonproliferative diabetic retinopathy had reduced vascular leakage or macular exudation after being treated orally with danegaptide, according to a study presented at Angiogenesis, Exudation, and Degeneration 2026.
Danegaptide (Breye Therapeutics) was well tolerated in the phase 1b study, paving the way for a phase 2 trial, according to a press release from Breye.
The results were presented by Carl D. Regillo, MD, director of the retina service at Wills Eye Hospital and a member of Breye’s






